POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial

Karimi, Y., Ghesquieres, H., Jurczak, W., Cheah, C. Y., Clausen, M. R., Lugtenburg, P., Cunningham, D., Do, Y. R., Lewis, D. J., Gasiorowski, R., Kim, T. M., van der Poel, M., Poon, M. L., Feldman, T., Linton, K. M., Sureda, A., Hutchings, M., Stirner, M. C., Liu, Y., … Thieblemont, C. (2023). POSTER: ABCL-500 Longer Follow-Up Reaffirms Subcutaneous Epcoritamab Induces Deep and Durable Complete Remissions in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Results From the Pivotal EPCORE NHL-1 Trial. Clinical Lymphoma Myeloma and Leukemia, 23, S203. https://doi.org/10.1016/s2152-2650(23)00718-8
Authors:
Yasmin Karimi
Hervé Ghesquières
Wojciech Jurczak
Chan Y. Cheah
Michael Roost Clausen
Pieternella J. Lugtenburg
David Cunningham
Young Rok
David Lewis
Robin Gasiorowski
Tae Min Kim
Marjolein van der Poel
Michelle Poon
Tatyana Feldman
Kim Linton
Anna Sureda
Martin Hutchings
Mariana Cota Stirner
Yan Liu
Nurgul Kilavuz
Mariana Sacchi
Catherine Thiéblemont
Affiliated Authors:
Chan Y. Cheah
David Cunningham
Robin Gasiorowski
Publication Type:
Article
Unique ID:
10.1016/s2152-2650(23)00718-8
Publication Date:
Data Source:
OpenAlex

Record Created: